{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-033990","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.053146+00:00","generated_at":"2026-06-04T22:21:01.241873+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Quoin Pharma reports Q4/FY2023 net loss $8.7M; cash runway to H2 2025; positive QRX003 data","bullets":["Net loss Q4 2023 $2.0M (flat YoY); FY2023 $8.7M vs $9.4M in 2022.","Cash & equivalents $10.7M as of Dec 31, 2023; plus $6.5M March 5 offering and $8M ELOC (pending shareholder approval).","Positive initial data from first 6 evaluable subjects: 5/6 had negligible/absent itch; all 6 showed skin score improvement.","No safety concerns reported in either ongoing Netherton Syndrome study; enrollment age lowered to 14+.","Expects cash runway to extend into H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-033990","json":"https://secwatch.observer/filing/0001104659-24-033990.json","markdown":"https://secwatch.observer/filing/0001104659-24-033990.md","text":"https://secwatch.observer/filing/0001104659-24-033990.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465924033990/0001104659-24-033990-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465924033990/tm248782d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:21:01.241873+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8803297a419f152bbd9fd1eddb970f2bb5c1ad24","claim":"Quoin Pharmaceuticals, Ltd. reported the quarter and year ended December 31, 2023 results: net income Net loss for the quarter ended December 31, 2023 was approximately $2.0 million compared to approximately $2.0 million f.","evidence_excerpt":"Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today provides a business update and announces financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465924033990/0001104659-24-033990-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Net income","value":"Net loss for the quarter ended December 31, 2023 was approximately $2.0 million compared to approximately $2.0 million f"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}